Gennova's mRNA vaccine to come in powder form; will stay stable at 2-8 °C

Gennova Biopharmaceuticals’ Covid-19 jab HGCO19, based on the mRNA technology platform, will be a lyophilized vaccine or one that is based on freeze-drying. This should help store the vaccine at much higher temperatures than the stringent sub-zero temperatures required to maintain a stable cold chain for other mRNA vaccines globally.
 
The lyophilized vaccine will come in a powder form and it will be mixed with diluents before administration.
 
In fact, Pfizer and BioNTech have already started a phase-3 study to evaluate the lyophilized (freeze-dried) formulation of the Pfizer-BioNTech vaccine, Pfizer noted on its website.
 
Gennova has got